Who is affected by this change?

This affects Independence Blue Cross Allergy & Immunology, Pulmonology providers on Commercial plans.

When does this change take effect?

This change is effective Dec 10, 2025.

Back to dashboard

CommercialCoverageMedium impact

08.00.55m, Omalizumab (Xolair®)

Independence Blue Cross·Allergy & Immunology, Pulmonology·Pharmacy

Effective date

Dec 10, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

The Omalizumab (Xolair®) pharmacy policy has been reissued with updates effective December 10, 2025. This is a commercial insurance policy change that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialty asthma and allergy medication.

Action Required

Action needed

By December 10, 2025: Review the updated Omalizumab (Xolair®) policy at the provided IBX URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures. Update billing workflows and staff training accordingly for patients receiving this medication.

Related policy hubs

Independence Blue Cross policies Allergy & Immunology Pulmonology